A PYMNTS Company

EU Probes Teva For Abuse Of Its Dominant Position

By  |  November 15, 2020

EU antitrust regulators are investigating Israeli drugmaker Teva over the possible abuse of its dominant position related to its multiple sclerosis medicine Copaxone, reported Reuters.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The EU competition enforcer raided Teva in October last year and in January this year as part of its investigation.

    Teva can face fines up to 10% of its global turnover if found guilty of breaching EU antitrust rules.

    The US government sued Teva in August, accusing the drugmaker of causing the submission of false claims to Medicare by using kickbacks to boost sales of Copaxone, one of its lucrative drugs.

    This is the company’s third run-in with EU antitrust regulators which have also charged the company with anti-competitive practices over its deal with rival Cephalon to delay selling a generic version of its sleep disorder drug modafinil.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.